Endotrophin, a multifaceted player in metabolic dysregulation and cancer progression, is a predictive biomarker for the response to PPARγ agonist treatment
Year: 2016
Type: editorial
Source: Diabetologia
Authors: Kai Sun, Jiyoung Park, Min Kim, Philipp E. Scherer
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: bronze
Funders: Cancer Prevention and Research Institute of Texas, University of Texas Health Science Center at Houston, National Research Foundation, Korea Health Industry Development Institute, National Research Foundation of Korea, Ministry of Education, Science and Technology, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, National Center for Advancing Translational Sciences
Awards: G1513834276, Center for Clinical and Translational Sciences (CCTS), G1889600028, G3244685553, G4993500047, G5957465968, Adiponectin, A Protein Secreted From Adipose Tissue, G6223515718, Novel Mechanisms Regulating the Adipocyte-Brain-Hepatocyte Axis, Endotrophin and the Obesity/Cancer Nexus: Role in Growth and Chemoresistance, White Adipose Tissue Physiology, Mitochondrial Function and Adiponectin
OpenAlex ID: W2527743582
